SBC Medical Group (NASDAQ:SBC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of SBC Medical Group (NASDAQ:SBC) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other research analysts have also recently weighed in on SBC. BTIG Research restated a “buy” rating and issued a $8.00 price objective on shares of SBC Medical Group in a report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of SBC Medical Group in a report on Wednesday, August 19th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.50.

SBC Medical Group Trading Up 8.2%

SBC opened at $5.14 on Friday. SBC Medical Group has a 52 week low of $2.78 and a 52 week high of $5.29. The business has a fifty day simple moving average of $3.70 and a 200-day simple moving average of $3.54. The firm has a market cap of $528.65 million, a P/E ratio of 10.94 and a beta of 0.63. The company has a quick ratio of 3.27, a current ratio of 3.31 and a debt-to-equity ratio of 0.09.

SBC Medical Group (NASDAQ:SBC) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.02). The firm had revenue of $49.19 million during the quarter, compared to analysts’ expectations of $45.37 million. SBC Medical Group had a net margin of 27.99% and a return on equity of 18.47%. On average, equities analysts expect that SBC Medical Group will post 0.44 earnings per share for the current year.

Hedge Funds Weigh In On SBC Medical Group

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE purchased a new stake in shares of SBC Medical Group during the second quarter worth approximately $35,000. Bank of New York Mellon Corp purchased a new stake in shares of SBC Medical Group in the 1st quarter valued at approximately $43,000. Deutsche Bank AG acquired a new stake in shares of SBC Medical Group in the 2nd quarter valued at $58,000. Williams & Novak LLC lifted its position in shares of SBC Medical Group by 31.2% during the 2nd quarter. Williams & Novak LLC now owns 18,686 shares of the company’s stock worth $58,000 after purchasing an additional 4,449 shares during the last quarter. Finally, Two Sigma Securities LLC acquired a new position in shares of SBC Medical Group during the second quarter worth $66,000. Hedge funds and other institutional investors own 60.82% of the company’s stock.

SBC Medical Group Company Profile

SBC Medical Group (NASDAQ: SBC) is a Japan-based medical services and management company focused primarily on the aesthetic medicine sector. Through its affiliated medical corporations and clinic network, the company supports the operation of facilities offering cosmetic surgery, cosmetic dermatology and related elective treatments.

The company provides a range of management and operational services to affiliated clinics, including branding and marketing, staff recruitment and training, purchasing, information technology, administrative support and business consulting.